JP2016513682A - 抗血漿カリクレイン抗体 - Google Patents

抗血漿カリクレイン抗体 Download PDF

Info

Publication number
JP2016513682A
JP2016513682A JP2016502334A JP2016502334A JP2016513682A JP 2016513682 A JP2016513682 A JP 2016513682A JP 2016502334 A JP2016502334 A JP 2016502334A JP 2016502334 A JP2016502334 A JP 2016502334A JP 2016513682 A JP2016513682 A JP 2016513682A
Authority
JP
Japan
Prior art keywords
antibody
pkal
isolated antibody
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513682A5 (enExample
Inventor
ニクソン，アンドリュー
ケンニストン，ジョン，エー．
コミュー，ステファン，アール．
Original Assignee
ダイアックス コーポレーション
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション, ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2016513682A publication Critical patent/JP2016513682A/ja
Publication of JP2016513682A5 publication Critical patent/JP2016513682A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
JP2016502334A 2013-03-15 2014-03-14 抗血漿カリクレイン抗体 Pending JP2016513682A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791822P 2013-03-15 2013-03-15
US61/791,822 2013-03-15
PCT/US2014/027100 WO2014152232A2 (en) 2013-03-15 2014-03-14 Anti-plasma kallikrein antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019167295A Division JP2020007354A (ja) 2013-03-15 2019-09-13 抗血漿カリクレイン抗体

Publications (2)

Publication Number Publication Date
JP2016513682A true JP2016513682A (ja) 2016-05-16
JP2016513682A5 JP2016513682A5 (enExample) 2017-04-13

Family

ID=51581689

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502334A Pending JP2016513682A (ja) 2013-03-15 2014-03-14 抗血漿カリクレイン抗体
JP2019167295A Pending JP2020007354A (ja) 2013-03-15 2019-09-13 抗血漿カリクレイン抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019167295A Pending JP2020007354A (ja) 2013-03-15 2019-09-13 抗血漿カリクレイン抗体

Country Status (10)

Country Link
US (4) US20160017055A1 (enExample)
EP (2) EP3594244A1 (enExample)
JP (2) JP2016513682A (enExample)
KR (1) KR20150132473A (enExample)
CN (3) CN118406688A (enExample)
AU (4) AU2014240045A1 (enExample)
CA (2) CA3208188A1 (enExample)
HK (1) HK1218762A1 (enExample)
IL (2) IL292121B2 (enExample)
WO (1) WO2014152232A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502572A (ja) * 2015-01-02 2018-02-01 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
KR102607829B1 (ko) * 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
CN108602893A (zh) * 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
KR20200067195A (ko) * 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제
AU2019328324B2 (en) * 2018-08-30 2025-06-19 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN114207135A (zh) 2019-06-11 2022-03-18 夏尔人类遗传性治疗公司 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
WO2021202948A2 (en) * 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN116829595A (zh) 2020-12-16 2023-09-29 武田药品工业株式会社 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
WO2022156799A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285507A1 (en) * 2007-03-21 2010-11-11 Je-Yeol Cho Plasma kallikrein fragments as diagnostic biomarkers for lung cancers
US20110200611A1 (en) * 2010-01-06 2011-08-18 Dyax Corp. Plasma kallikrein binding proteins
WO2012094587A1 (en) * 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5444156A (en) 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1987005396A1 (en) 1986-03-03 1987-09-11 Brigham And Women's Hospital A method for evaluating nephrotoxicity
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE165516T1 (de) 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
EP0644946A4 (en) 1992-06-10 1997-03-12 Us Health VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69433461T2 (de) 1993-09-15 2004-11-18 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter Alphavirus Vektor
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
KR100241300B1 (ko) 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
AU2585395A (en) 1994-05-09 1995-11-29 Chiron Corporation Retroviral vectors having a reduced recombination rate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0953052B1 (en) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Crossless retroviral vectors
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU3734900A (en) 1999-03-09 2000-09-28 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
ES2392073T3 (es) 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP2070539A1 (de) 2002-08-21 2009-06-17 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-Amino-Piperidin-1-YL]-Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
WO2005075665A2 (en) 2004-02-03 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
RS50982B (sr) 2004-02-18 2010-10-31 Boehringer Ingelheim International Gmbh. 8-[3-amino piperidin-1-il]-ksantini, njihovo dobijanje i njihova primena kao dpp-iv inhibitora
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
PT2374472T (pt) 2006-03-16 2018-08-08 Dyax Corp Composições e métodos para o tratamento de afeções oftalmológicas
AU2008288772A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
EP2697196A1 (en) 2011-04-13 2014-02-19 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
CA3051418C (en) 2011-05-02 2021-05-18 Millennium Pharmaceuticals, Inc. Methods of treating inflammatory bowel disease
CN104271122A (zh) 2012-02-16 2015-01-07 桑塔鲁斯股份有限公司 抗vla1(cd49a)抗体药物组合物
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
EP4234583A3 (en) 2013-01-20 2024-01-24 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
TR201904638T4 (tr) 2013-01-20 2019-04-22 Dyax Corp pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi.
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
AU2015209481C1 (en) 2014-01-21 2020-10-29 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
KR102607829B1 (ko) 2015-03-30 2023-12-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
AU2019328324B2 (en) 2018-08-30 2025-06-19 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US20200317815A1 (en) 2019-03-14 2020-10-08 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285507A1 (en) * 2007-03-21 2010-11-11 Je-Yeol Cho Plasma kallikrein fragments as diagnostic biomarkers for lung cancers
US20110200611A1 (en) * 2010-01-06 2011-08-18 Dyax Corp. Plasma kallikrein binding proteins
WO2012094587A1 (en) * 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018502572A (ja) * 2015-01-02 2018-02-01 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2020186248A (ja) * 2015-01-02 2020-11-19 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP7003347B2 (ja) 2015-01-02 2022-02-04 武田薬品工業株式会社 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2022023038A (ja) * 2015-01-02 2022-02-07 武田薬品工業株式会社 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
US11390687B2 (en) 2015-01-02 2022-07-19 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and Factor XII
JP7241827B2 (ja) 2015-01-02 2023-03-17 武田薬品工業株式会社 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023065659A (ja) * 2015-01-02 2023-05-12 武田薬品工業株式会社 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP7635285B2 (ja) 2015-01-02 2025-02-25 武田薬品工業株式会社 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
US12240918B2 (en) 2015-01-02 2025-03-04 Takeda Pharmaceutical Company Limited Bispecific antibodies against plasma kallikrein and factor XII
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
US12415866B2 (en) 2015-07-21 2025-09-16 Takeda Pharmaceutical Company Limited Monoclonal antibody inhibitor of Factor XIIa

Also Published As

Publication number Publication date
US11299553B2 (en) 2022-04-12
AU2021200144B2 (en) 2024-06-20
IL292121B1 (en) 2023-10-01
CA2906624A1 (en) 2014-09-25
AU2024219756A1 (en) 2024-10-10
IL241334B (en) 2022-05-01
AU2014240045A1 (en) 2015-09-10
IL241334A0 (en) 2015-11-30
AU2019200638A1 (en) 2019-02-21
EP3594244A1 (en) 2020-01-15
JP2020007354A (ja) 2020-01-16
IL292121B2 (en) 2024-02-01
CN111704672A (zh) 2020-09-25
KR20150132473A (ko) 2015-11-25
US20250129182A1 (en) 2025-04-24
CN111704672B (zh) 2024-06-04
US20230002509A1 (en) 2023-01-05
IL292121A (en) 2022-06-01
EP2970502A4 (en) 2016-11-30
US12110343B2 (en) 2024-10-08
US20160017055A1 (en) 2016-01-21
WO2014152232A3 (en) 2014-11-13
CN105051068A (zh) 2015-11-11
AU2019200638B2 (en) 2021-01-28
BR112015022282A2 (pt) 2017-10-10
HK1218762A1 (zh) 2017-03-10
AU2021200144A1 (en) 2021-03-18
CA3208188A1 (en) 2014-09-25
US20190185580A1 (en) 2019-06-20
EP2970502A2 (en) 2016-01-20
CN118406688A (zh) 2024-07-30
WO2014152232A2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US12110343B2 (en) Anti-plasma kallikrein antibodies
JP7550251B2 (ja) 糖尿病黄斑浮腫の治療のための組成物および方法
JP2017512790A5 (enExample)
HK40112846A (zh) 抗血浆激肽释放酶抗体
HK40021386A (en) Anti-plasma kallikrein antibodies
BR112015022282B1 (pt) Anticorpo isolado que liga calicreína de plasma humana (pkal), composição farmacêutica e uso de uma composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190514